Dupilumab, a fully human, monoclonal antibody inhibiting signaling of both interleukin (IL)‐4 and IL‐13 is the first and only targeted biologic treatment approved for moderate to severe AD until now.2 The gene discussed is IL4; the disease is Alzheimer disease.